1) WHO. Launch of the global strategy to accelerate the elimination of cervical cancer. https://www.who.int/news-room/events/detail/2020/11/17/default-calendar/launch-of-the-globalstrategy-to-accelerate-the-elimination-of-cervical-cancer
2) Cohen PA, et al. Cervical cancer. Lancet. 2019;393(10167):169-82.
3) 日本産科婦人科学会. 子宮頸がん. https://www.jsog.or.jp/modules/diseases/index.php?content_id=10
4) Saraiya M, et al;HPV Typing of Cancers Workgroup. US assessment of HPV types in cancers:implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086.
5) de Sanjose S, et al;Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective crosssectional worldwide study. Lancet Oncol. 2010;11(11):1048-56.
6) Petrosky E, et al;Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine:updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-4.
7) 日本性感染症学会編. 性感染症診断・治療ガイドライン2020. 東京, 診断と治療社, 2020.
8) Venkatesan NN, et al. Recurrent respiratory papillomatosis. Otolaryngol Clin North Am. 2012;45(3):671-94, viii-ix.
9) Holowaty P, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91(3):252-8.
10) Quinn M, et al. Effect of screening on incidence of and mortality from cancer of cervix in England:evaluation based on routinely collected statistics. BMJ. 1999;318(7188):904-8.
11) Franceschi S, et al. EUROGIN 2008 roadmap on cervical cancer prevention. Int J Cancer. 2009;125(10):2246-55.
12) Fangjian Guo, et al. Cervical cancer incidence in young U.S. females after human papillomavirus vaccineintroduction. Am J Prev Med. 2018;55(2):197-204.
13) Matsumoto K, et al. Early impact of the Japanese immunization program implemented before the HPV vaccination crisis. Int J Cancer. 2017;141(8):1704-6.
14) Ozawa N, et al. Beneficial effects of human papillomavirus vaccine for prevention of cervical abnormalities in Miyagi, Japan. Tohoku J Exp Med. 2016;240(2):147-51.
15) Ikeda S, et al. Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan:A nationwide case-control study. Cancer Sci. 2021;112(2):839-46.
16) Markowitz LE, et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968.
17) Cameron RL, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis. 2016;22(1):56-64.
18) CDC. HPV vaccine schedules and dosing. https://www.cdc.gov/hpv/hcp/schedulesrecommendations.html
19) Barnabas RV, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022;1(5):EVIDoa2100056.
20) Markowitz LE, Unger ER. Human Papillomavirus vaccination. N Engl J Med. 2023;388(19):1790-8.
21) CDC. HPV vaccine safety and effectiveness. https://www.cdc.gov/vaccines/partners/downloads/teens/vaccine-safety.pdf
22) 第18回厚生科学審議会予防接種・ワクチン分科会予防接種基本方針部会 ワクチン評価に関する小委員会. 組換え沈降9価ヒトパピローマウイルス様粒子ワクチン(9価HPVワクチン)について. https://www.mhlw.go.jp/content/10601000/000907614.pdf
24) Lin S, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021;127(21):4030-9.